Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7060MR)

This product GTTS-WQ7060MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7060MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3380MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ7002MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA F-627
GTTS-WQ3617MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ11157MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ14603MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ8301MR IVTScrip™ mRNA-Anti-GLP1R, HM-12525A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HM-12525A
GTTS-WQ12536MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ7375MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW